Screener
Opko Health OPK Pharmaceutical — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Opko Health in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Opko Health’s 10-Q, filed July 27, 2026.
- Filed
- Jul 27, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-318090
| (In thousands) / Revenue from services: / Pharmaceutical | For the three months ended June 30, 2026 / — | For the three months ended June 30, 2025 / — | For the six months ended June 30, 2026 / — | For the six months ended June 30, 2025 / — |
|---|---|---|---|---|
| Corporate | 12,434 | 13,031 | 20,685 | 21,451 |
| $52,924 | $59,597 | $101,531 | $118,683 | |
| Research and development: | ||||
| Pharmaceutical | $32,739 | $29,778 | $61,492 | $60,016 |
| Diagnostics | 294 | 484 | 606 | 1,022 |
| Corporate | 133 | 80 | 267 | 145 |
| $33,166 | $30,342 | $62,365 | $61,183 | |
| Amortization of intangible assets: |
Item 1. Financial Statements
FAQ
- What is Opko Health's pharmaceutical — research and development expense?
- Opko Health (OPK) reported pharmaceutical — research and development expense of $32.74M in Q2 2026.
- How has Opko Health's pharmaceutical — research and development expense changed year-over-year?
- Opko Health's pharmaceutical — research and development expense increased by 9.9% year-over-year, from $29.78M to $32.74M.
- What is the long-term trend for Opko Health's pharmaceutical — research and development expense?
- Over 2 years (2023 to 2025), Opko Health's pharmaceutical — research and development expense has grown at a 18.4% compound annual growth rate (CAGR), from $87.01M to $121.91M.
- What does pharmaceutical — research and development expense mean?
- The costs incurred by the pharmaceutical segment to discover, develop, and test new drug candidates or improve existing pharmaceutical products. This reflects the company's investment in future growth and long-term pipeline innovation.
Ask your AI about Opko Health's pharmaceutical — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude